PTP1B blocking improves memory in Alzheimer's mouse models
Updated
Updated · Türkiye Today · May 3
PTP1B blocking improves memory in Alzheimer's mouse models
7 articles · Updated · Türkiye Today · May 3
Cold Spring Harbor Laboratory researchers led by Nicholas Tonks reported in PNAS that inhibiting the protein helped microglia clear amyloid-beta plaques more effectively.
The team said PTP1B interacts with SYK, and removing or blocking it strengthened microglial signalling, making the brain's immune cells more active in the mice.
Researchers said the approach could complement approved drugs in combination therapy, as debate continues over the limited clinical benefit of some anti-amyloid treatments.
As new drugs fight plaques, could an immune-booster be the missing piece to finally slow Alzheimer's progression?
Could a drug target for diabetes also reboot the brain's immune system to fight Alzheimer's disease?
PTP1B Inhibition Reverses Alzheimer's Symptoms by Revitalizing Microglia and Restoring Metabolic Function
Overview
A breakthrough study in February 2026 showed that blocking the protein PTP1B in Alzheimer's mouse models revitalizes the brain's immune cells, microglia, by restoring SYK signaling and activating energy pathways. This reactivation enables microglia to clear toxic amyloid-beta plaques, leading to reversed memory loss and improved learning. PTP1B inhibition also enhances brain support systems like BDNF signaling and synaptic stability, further boosting cognition. Importantly, this approach addresses metabolic dysfunction linked to Alzheimer's and shows promise in Parkinson's disease models. Combining PTP1B inhibitors with existing therapies could enhance plaque clearance, offering a new, multi-targeted strategy against neurodegeneration.